A Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Trial Profile

A Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Not yet recruiting
Phase of Trial: Phase 0

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Cyclophosphamide (Primary) ; IMC CS4 (Primary) ; Pembrolizumab (Primary) ; Tumour cell vaccine-GVAX (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 02 Mar 2018 Planned End Date changed from 1 Nov 2019 to 1 Mar 2020.
    • 02 Mar 2018 Planned primary completion date changed from 1 Nov 2019 to 1 Mar 2020.
    • 02 Mar 2018 Planned initiation date changed from 1 Nov 2017 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top